Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Fluicell

10.60 SEK

+2.91 %

Less than 1K followers

FLUI

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+2.91 %
-17.19 %
-17.83 %
-7.83 %
-26.13 %
-37.43 %
-94.24 %
-98.84 %
-99.04 %

Fluicell operates in biotechnology. The company conducts research and development in the processing of cell composition in the development of new drugs. The company has developed a product portfolio consisting of patented research instruments, which are used to study, analyze and ultimately process cells. In addition, there is expertise in 2D/3D printing. Fluicell was founded in 2012 and is headquartered in Gothenburg.

Read more
Market cap
14.56M SEK
Turnover
2.77K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.2.
2026

Annual report '25

8.5.
2026

Interim report Q1'26

14.5.
2026

General meeting '26

ShowingAll content types
Third party research

Fluicell: Accelerating Towards further Milestones - Analyst Group

Fluicell AB (publ) (”Fluicell” or “the Company”) offers innovative R&D instruments for both single-cell analysis and 3D bioprinting business segments in which we forecast will enter a fast-growing pace, where a revenue of SEK 68.6m is estimated for the...

Fluicell

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Third party research

Fluicell : Ready to Intensify Sales Activities - Analyst Group

Fluicell offers innovative R&D instruments for single-cell analysis and 3D bioprinting, a business area which we forecast will enter a fast-growth pace, where a revenue of SEK 68.6m is estimated for the year 2026. Based on an applied P/S-multiple of ...

Fluicell
Third party research

Fluicell: Comment, Q3-22 Report - Analyst Group

Summary of Operating Activities During Q3-22, the revenue amounted to SEK 0.51m, compared to SEK 1.1m in Q3-21, which corresponds to a YoY decrease of 52%. Compared to the previous quarter of Q2-22 where the revenue amounted to SEK 0.49m, the increase...

Fluicell
Third party research

Fluicell: Clinical Results on the Horizon - Analyst Group

Fluicell offers innovative R&D instruments for single-cell analysis and 3D bioprinting, a business area which we forecast will enter a fast-growth pace, where a revenue of SEK 68.6m is estimated for the year 2026. Based on an applied P/S-multiple of ...

Fluicell
Third party research

Analyst Group Initiates Equity Research Coverages of Fluicell

Our analyst summarizes the investment case:“Fluicell offers innovative R&D instruments for single-cell analysis and 3D bioprinting, a business area which we forecast will enter into a fast-growth pace, where a revenue of SEK 68.6M is estimated for the...

Fluicell
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.